Sana Biotechnology Inc (NASDAQ: SANA) has seen a decline in its stock price by -2.85 in relation to its previous close of 2.81. However, the company has experienced a 5.00% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-23 that Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression
Is It Worth Investing in Sana Biotechnology Inc (NASDAQ: SANA) Right Now?
SANA has 36-month beta value of 1.86. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SANA is 125.44M, and currently, short sellers hold a 34.73% ratio of that float. The average trading volume of SANA on July 01, 2025 was 4.09M shares.
SANA’s Market Performance
The stock of Sana Biotechnology Inc (SANA) has seen a 5.00% increase in the past week, with a 20.26% rise in the past month, and a 59.65% gain in the past quarter. The volatility ratio for the week is 8.13%, and the volatility levels for the past 30 days are at 10.53% for SANA. The simple moving average for the past 20 days is 2.25% for SANA’s stock, with a -0.16% simple moving average for the past 200 days.
Analysts’ Opinion of SANA
Many brokerage firms have already submitted their reports for SANA stocks, with Citizens JMP repeating the rating for SANA by listing it as a “Mkt Outperform.” The predicted price for SANA in the upcoming period, according to Citizens JMP is $5 based on the research report published on March 18, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see SANA reach a price target of $7. The rating they have provided for SANA stocks is “Buy” according to the report published on March 14th, 2025.
SANA Trading at 25.08% from the 50-Day Moving Average
After a stumble in the market that brought SANA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.11% of loss for the given period.
Stock Fundamentals for SANA
The total capital return value is set at -0.52. Equity return is now at value -71.44, with -37.04 for asset returns.
Based on Sana Biotechnology Inc (SANA), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at -2.26.
Currently, EBITDA for the company is -251.27 million with net debt to EBITDA at 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.40.
Conclusion
To put it simply, Sana Biotechnology Inc (SANA) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
